• Concanavalin A (ConA) induced T cell infiltration and liver injury is a model for acute hepatitis• Important cell types include most white blood cells as well as stromal cells• The ConA model has successfully been used to discover new pathways in hepatitis research• New therapeutic interventions for hepatitis were discovered using the ConA model
Introduction Autoimmune hepatitisAutoimmune Hepatitis (AIH) is a chronic liver disease associated with raised plasma liver enzymes like transaminases and the presence of autoantibodies [1,2]. The initial trigger of the disease is unknown but different genetic risk factors have been identified [3,4]. In general, it is believed that multiple perturbations, unidentified environmental factors or drugs and the loss of self-tolerance are needed for the onset and development of AIH. The mechanisms for loss of self-tolerance leading to auto reactivity remain unclear but major contributors such as impaired thymic negative selection and expansion of promiscuous T cell clones are suggested [5]. In AIH, presentation of a self-antigen peptide within a Major Histocompatibility (MHC) II molecule by professional Antigen Presenting Cells (APCs) initiates liver damage. This antigen presentation, in combination with exposure to various cytokines, drives the differentiation of uncommitted CD4 helper T cells and immune reaction that is skewed to a Th1 and Th17 response. However, the Th2 response cannot be ignored because it is important in the production of auto-antibodies, which trigger cellular cytotoxicity and complement activation [6,7]. The current standard treatment of AIH patients consists of non-specific immune suppressing drugs such as corticosteroids in combination with azathioprine, which leads to a decrease in serum aminotransferase levels [8].
AIH animal modelsDespite extensive research on the pathogenesis of AIH, the details of the mechanism remain elusive and the current treatments are non-specific and insufficient. The need for faithful and reliable animal models is therefore high. However, finding a suitable animal model is difficult due to the fact that AIH lacks a precise time of onset, etiological agent and the clinical phenotype is variable. According to Czaja et al., the current AIH models can be divided in two categories: the pathogenic and therapeutic models [1]. Pathogenic models focus on characterization of individual mechanisms contributing to occurrence and severity of the disease. In these perturbed models, individual pathways can be isolated and manipulated in a genetic homogenous background. Next to transgenic models in which target antigens are expressed under the control of liver-specific promoters, several inducible models such as the D Galactosamine (GalN) in com
HSOA Journal of Gastroenterology & Hepatology Research
Review Article
AbstractAutoimmune Hepatitis (AIH) is a chronic liver disease where presentation of a self-antigen peptide by professional antigen presenting cells initiates liver damage and drives the differentiation of uncommitted CD4 helpe...